CurrentAmbetter NevadaPolicy CP.MP.150

Phototherapy for Neonatal Hyperbilirubinemia

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.150 alerts

Get alerted when Policy CP.MP.150 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity criteria and coverage stance for home and inpatient phototherapy for treatment of neonatal hyperbilirubinemia for affected newborns and their providers.

Policy Summary

PayerAmbetter Nevada

PolicyPhototherapy for Neonatal Hyperbilirubinemia

Policy CodePolicy CP.MP.150

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionDocument daily total serum bilirubin (TSB) during home phototherapy and ensure primary care follow-up within 12–24 hours.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥38wgestational age eligibility for home phototherapy

≥48hminimum infant age for home phototherapy

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmbetter NevadaPolicy CP.MP.150

Phototherapy for Neonatal Hyperbilirubinemia

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.150 alerts

Get alerted when Policy CP.MP.150 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity criteria and coverage stance for home and inpatient phototherapy for treatment of neonatal hyperbilirubinemia for affected newborns and their providers.

Policy Summary

PayerAmbetter Nevada

PolicyPhototherapy for Neonatal Hyperbilirubinemia

Policy CodePolicy CP.MP.150

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionDocument daily total serum bilirubin (TSB) during home phototherapy and ensure primary care follow-up within 12–24 hours.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥38wgestational age eligibility for home phototherapy

≥48hminimum infant age for home phototherapy

460–490nmphototherapy wavelength

TSB dailybilirubin monitoring frequency

E0202,S9098HCPCS codes referenced

Medical Necessity and Coverage Criteria

Home phototherapy (medical necessity)

Home phototherapy is medically necessary when ALL of the following are met:

Home phototherapy core criteria: Infant is ≥ 38 weeks gestation; infant status is one of: (a) previously discharged and readmission is being considered only for hyperbilirubinemia, or (b) currently inpatient and ready for discharge except for needing treatment for elevated bilirubin; infant is feeding well, active, and clinically well; a primary care provider is willing to manage home care with established follow-up within 12 to 24 hours after discharge; infant is ≥ 48 hours old; an LED-based phototherapy device will be available in the home without delay; no previous phototherapy; total serum bilirubin (TSB) will be measured daily; infant lacks the listed risk factors (see child nodes); and TSB is within the age-specific levels in Table 1 for infants without risk factors.See Table 1 age-specific TSB levels (hours of life) in policy text

Table 1 gives conservative TSB cutoffs by age; daily TSB monitoring required.

Risk factor exclusions (infant must have NONE of the following)

Isoimmune hemolytic disease (positive direct antiglobulin test), G6PD deficiency, or other hemolytic disease.
Hypoxic ischemic encephalopathy (HIE) / asphyxia.
Temperature instability.
Sepsis.
Acidosis.
Albumin < 3.0 g/dL (if measured).
Birth weight < 2500 g.
Significant cephalohematoma or bruising.
Weight loss ≥ 10%.
Elevated direct-reacting / conjugated bilirubin.
Jaundice appearing in the first 24 hours of life.
Laboratory or clinical evidence of hypothyroidism.
Significant clinical instability in the previous 24 hours.
Family history (parent or sibling) requiring phototherapy or exchange transfusion.
Exclusive breastfeeding or chest feeding with suboptimal intake (≥ 10% weight loss).
Down syndrome.
Macrosomic infant of a diabetic mother.

Inpatient phototherapy / Exchange transfusion

Inpatient phototherapy and exchange transfusion:

Inpatient phototherapy / exchange transfusion criteria: When criteria for home phototherapy are not met, inpatient phototherapy (when indicated) and exchange transfusion are medically necessary when meeting the most current nationally recognized decision support tools (e.g., AAP guidelines / bili risk tool). Admission for inpatient phototherapy is indicated if the TSB concentration is more than 1 mg/dL above the AAP phototherapy treatment threshold in the AAP bili risk calculator.Refer to the AAP bili risk tool (peditools.org/bili2022) and current nationally recognized decision support tools.

Infants are NOT eligible for home phototherapy if they have any of the following risk factors: isoimmune hemolytic disease (e.g., positive direct antiglobulin test), G6PD or other hemolytic disease, hypoxic ischemic encephalopathy/asphyxia, temperature instability, sepsis, acidosis, albumin < 3.0 g/dL (if measured), birth weight < 2500 g, significant cephalohematoma or bruising, weight loss ≥ 10%, elevated direct (conjugated) bilirubin, jaundice appearing in the first 24 hours of life, laboratory or clinical evidence of hypothyroidism, significant clinical instability in the previous 24 hours, a family history (parent or sibling) of requiring phototherapy or exchange transfusion, exclusive breastfeeding with suboptimal intake (≥ 10% weight loss), Down syndrome, or macrosomic infant of a diabetic mother.

Coverage determinations informed by this clinical policy are guidance to assist medical necessity review but remain subject to the member's coverage documents and applicable law. Decisions about payment and benefits are governed by the plan's evidence of coverage, contracts, state and federal requirements, and Health Plan administrative policies and procedures; specific exclusions and limitations are defined in those documents and control when discrepancies exist.

When an infant meets all stated criteria for home phototherapy, inpatient phototherapy is considered not medically necessary unless there is documentation of extenuating circumstances (for example, expected inability to adhere to therapy at home). In other words, eligible infants should be managed with home phototherapy rather than inpatient care unless clear, documented reasons require inpatient treatment.

Coding, Codes and Technical Parameters

HCPCS Codes referencedHCPCS

E0202	Phototherapy (bilirubin) light with photometer.
S9098	Home visit, phototherapy services (e.g., Bili-lite), including equipment rental, nursing services, blood draw, supplies, and other services, per diem

Phototherapy irradiance

Required irradiance≥ 30 µW/cm2 per nm measured at the infant's skin (directly below the center of the phototherapy unit)

Measurement locationIrradiance must be measured at the infant's skin directly beneath the center of the unit

PurposeDefines intensive/adequate phototherapy delivery to reduce bilirubin effectively

Coding/threshold referenceUsed as the irradiance threshold for intensive phototherapy in clinical criteria and coding guidance

Provider Responsibilities, Prior Auth, and Billing Guidance

Billing Rule

Use HCPCS E0202 and S9098; obtain prior authorization per plan rules

Report HCPCS code E0202 for phototherapy (bilirubin) light with photometer and S9098 for per diem home phototherapy services (home visit, phototherapy services including equipment rental, nursing services, blood draw, supplies, and other services). Follow the Health Plan's prior authorization process for these codes when submitting requests for home phototherapy equipment or per‑diem home services.

HCPCS E0202 — Phototherapy (bilirubin) light with photometer.
HCPCS S9098 — Home visit, phototherapy services (per diem).
Submit prior authorization per Health Plan administrative procedures for durable medical equipment and per‑diem home services.

Prior Authorization

Clinical Background

Neonatal hyperbilirubinemia is a common cause of physiologic jaundice in newborns; markedly elevated unconjugated bilirubin can lead to acute bilirubin-induced neurologic dysfunction and kernicterus if untreated. Phototherapy (preferably LED blue‑green light approximately 460–490 nm with intensive delivery defined as ≥ 30 µW/cm2 per nm measured at the infant's skin) converts bilirubin to water‑soluble isomers and is the first‑line treatment to lower total serum bilirubin. For otherwise healthy term infants who meet conservative age- and TSB-based thresholds, and who have adequate feeding and close follow-up, home phototherapy is an acceptable alternative to inpatient treatment when the policy criteria are satisfied.

Definitions and Phototherapy Types

Phototherapy (conventional)

Spectral range (conventional phototherapy)Blue-green spectrum, approximately 460–490 nm

MechanismSingle light source converts unconjugated bilirubin into water‑soluble isomers to lower TSB

Preferred light typeLED-based devices in the blue‑green spectrum are preferred for home and inpatient phototherapy

Clinical roleFirst-line treatment for neonatal hyperbilirubinemia to reduce rate of rise and risk of kernicterus

Intensive phototherapy (preferred delivery)

Intensity threshold (intensive phototherapy)Irradiance ≥ 30 µW/cm2 per nm measured at the infant's skin (directly below the center of the unit)

Policy Summary

PayerAmbetter Nevada

PolicyPhototherapy for Neonatal Hyperbilirubinemia

Policy CodePolicy CP.MP.150

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionDocument daily total serum bilirubin (TSB) during home phototherapy and ensure primary care follow-up within 12–24 hours.

SourceLink

On This Page

Follow Health Plan prior authorization procedures (policy guides medical necessity only)

Prior authorization decisions are governed by the Health Plan's administrative procedures and applicable coverage documents; this policy provides medical necessity guidance to assist those decisions but does not replace plan PA requirements.

Use this clinical policy only as guidance; follow the Health Plan's published prior authorization steps and requirements when requesting coverage.
Codes referenced in the policy are informational; inclusion does not guarantee coverage—verify PA rules before claim submission.

Step Therapy

Prefer home phototherapy when all home criteria are met; avoid inpatient admission

When an infant meets all home phototherapy criteria (including gestational age, clinical stability, feeding, available LED device, daily TSB monitoring, absence of listed risk factors, and TSB within Table 1 limits), provide phototherapy at home rather than admit— inpatient phototherapy is not medically necessary if home criteria are met unless extenuating circumstances are documented.

Ensure established PCP follow‑up within 12–24 hours and availability of LED device at home before discharging for home phototherapy.
Document any extenuating circumstances if recommending inpatient care despite meeting home criteria.

Note

No step therapy requirements specified

There are no step‑therapy sequencing requirements specified in this policy; it does not prescribe prior trials of alternate therapies before home or inpatient phototherapy.

This policy states home phototherapy is preferred when criteria are met but does not list step therapy protocols.

Documentation Required

Document daily TSB and follow CPT/HCPCS coding guidance when billing

Document daily total serum bilirubin (TSB) measurements while the infant is receiving home phototherapy and follow applicable CPT/HCPCS coding guidance when billing for services and equipment.

Record daily TSB results in the medical record during home phototherapy as required by the coverage criteria.
Reference current CPT/HCPCS coding guidance prior to claim submission; codes in the policy are informational only.

Documentation Required

Provider retains responsibility for clinical judgment and documentation

Providers must exercise professional medical judgment in treatment decisions and documentation; this policy is guidance and not medical advice—providers remain responsible for clinical care and compliance with documentation standards.

Ensure clinical decisions and recordkeeping reflect professional standards and the individual patient's needs.
Retain documentation showing rationale when deviating from policy recommendations.

Denial Risk

Admit for inpatient phototherapy if TSB > 1 mg/dL above AAP threshold

Admit the infant for inpatient phototherapy if the total serum bilirubin (TSB) concentration is more than 1 mg/dL above the AAP phototherapy treatment threshold as indicated by the AAP bili risk calculator.

Use the AAP hyperbilirubinemia risk calculator (https://peditools.org/bili2022/index.php) to determine the treatment threshold and whether TSB exceeds it by >1 mg/dL.

Denial Risk

Coverage subject to member contract, exclusions, and applicable laws — noncompliance may cause denial

Coverage and administration of benefits are subject to the terms, conditions, exclusions and limitations of the member's coverage documents and to applicable state and federal requirements; lack of contract or regulatory compliance may result in denial of coverage.

Verify member coverage, contract exclusions, and any state Medicaid or Medicare requirements before authorizing or billing for services.
When conflicts exist, state Medicaid provisions or applicable law take precedence over this policy.

Preferred deliveryDelivers high irradiance to maximize bilirubin photo‑isomerization and clinical effectiveness

Clinical indicationUsed when intensive phototherapy is indicated by bilirubin levels or clinical risk factors

Measurement guidanceIrradiance should be verified at the infant's skin surface beneath the phototherapy unit